ТЕСТОСТЕРОН И СИМПТОМЫ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ У МУЖЧИН (ЛИТЕРАТУРНЫЙ ОБЗОР)

Библиографические ссылки:

Alcaraz A., Carballido-Rodríguez J., Unda-Urzaiz M. et al. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment – the QUALIPROST study. Int Urol Nephrol. 2016; 48(5): 645–656. https://doi.org/10.1007/s11255-015-1206-7

GBD 2019 Benign Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2022; 3(11): e754–e776. https://doi.org/10.1016/S2666-7568(22)00213-6

Egan K.B. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016; 43(3): 289–297. https://doi.org/10.1016/j.ucl.2016.04.001

Франк М.А., Гомжин А.И. Возрастной гипогонадизм – медицинская и социальная проблема. Уральский медицинский журнал. 2006; 8: 38–42. – EDN KVPKSZ.

Liu D., Li C., Li Y. et al. Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019. World J Urol. 2023; 41(12): 3629–3634. https://doi.org/10.1007/s00345-023-04658-8

Pradidarcheep W. Lower urinary tract symptoms and its potential relation with late-onset hypogonadism. Aging Male. 2008; 11(2): 51–55. https://doi.org/10.1080/13685530801954026

Holm-Larsen T., Van den Ende M., Wendelboe H.G. et al. The cost of lifelong LUTS – a systematic literature review. Neurourol Urodyn. 2024; 43(5): 1058–1065. https://doi.org/10.1002/nau.25389

Giulioni C., Cafarelli A., Piazza P. et al. Efficacy and safety of endourological surgery for managing overactive bladder symptoms in benign prostatic hyperplasia: a systematic review and meta-analysis. Int Neurourol J. 2026; 30(1): 44–56. https://doi.org/10.5213/inj.2550188.094

Shapiro K.K., Brucker B.M. Treatment of overactive bladder in men: is it really different? Neurourol Urodyn. 2022; 41(8): 1975–1982. https://doi.org/10.1002/nau.25000

Lee H., Hwang E.C., Oh C.K. et al. Testosterone replacement in men with sexual dysfunction. Cochrane Database Syst Rev. 2024; 1: CD013071. https://doi.org/10.1002/14651858.CD013071.pub2

Jung J.H., Kim J., MacDonald R. et al. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2017; 11: CD012615. https://doi.org/10.1002/14651858.CD012615.pub2

Ибишев Х.С., Хрипун И.А., Гусова З.Р. и др. Проблема дефицита тестостерона и эректильной дисфункции у мужчин (обзор литературы). Урология. 2014; 6: 104–107. – EDN PJIKST.

Liu Z.Y., Zhou R.Y., Lu X. et al. Identification of late-onset hypogonadism in middle-aged and elderly men from a community of China. Asian J Androl. 2016; 18(5): 747–753. https://doi.org/10.4103/1008-682X.160883

Diokno A.C. The role of testosterone in men's health: is it time for a new approach? Int Urol Nephrol. 2022; 54(11): 2767–2774. https://doi.org/10.1007/s11255-022-03292-4

Araujo A.B., O'Donnell A.B., Brambilla D.J. et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004; 89(12): 5920–5926. https://doi.org/10.1210/jc.2003-031719

Lee H., Hwang E.C., Oh C.K. et al. Testosterone replacement in men with sexual dysfunction: an abridged version of the Cochrane Systematic Review. World J Mens Health. 2025; 43(3): 539–551. https://doi.org/10.5534/wjmh.240146

Hudson J., Cruickshank M., Quinton R. et al. Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis. Lancet Healthy Longev. 2023; 4(10): e561–e572. https://doi.org/10.1016/S2666-7568(23)00169-1

Mohler E.R. 3rd, Ellenberg S.S., Lewis C.E. et al. The effect of testosterone on cardiovascular biomarkers in the Testosterone Trials. J Clin Endocrinol Metab. 2018; 103(2): 681–688. https://doi.org/10.1210/jc.2017-02243

Гусова З.Р., Ибишев Х.С., Дзантиева Е.О., Коган М.И. Возрастной андрогенный дефицит у мужчин: лечить, не лечить, кому лечить? Вестник урологии. 2016; 1: 72–85. – EDN WZQHQX.

Yafi F.A., Dewitte M., Elterman D. et al. Lower urinary tract symptoms and male sexual function: recommendations from the fifth international consultation on sexual medicine (ICSM 2024). Sex Med Rev. 2026; 14(1): qeaf071. https://doi.org/10.1093/sxmrev/qeaf071

O'Mahony C.J., Arshad M.A., Norton S.M. Testosterone and lower urinary tract symptoms: a narrative review. Curr Urol Rep. 2025; 26(1): 75. https://doi.org/10.1007/s11934-025-01307-y

Жиенбаев Е.Р., Бейсенов К.Т. Терапия метаболического синдрома и возрастного гипогонадизма у мужчин. Вестник Кыргызской государственной медицинской академии имени И.К. Ахунбаева. 2023; 3: 55–62. – EDN YJSUGB.

Лебедева Н.Б., Гофман В.В. Взаимосвязь возрастного гипогонадизма с риском развития сердечно-сосудистых заболеваний. Фундаментальная и клиническая медицина. 2020; 5(2): 60–66. – EDN TLIIKO.

Yuan X., Xiong X., Xue J. Effect of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and network meta-analysis. J Evid Based Med. 2024; 17(3): 490–502. https://doi.org/10.1111/jebm.12628

Rastrelli G., Vignozzi L., Corona G., Maggi M. Testosterone and benign prostatic hyperplasia. Sex Med Rev. 2019; 7(2): 259–271. https://doi.org/10.1016/j.sxmr.2018.10.006

Traish A.M., Johansen V. Impact of testosterone deficiency and testosterone therapy on lower urinary tract symptoms in men with metabolic syndrome. World J Mens Health. 2018; 36(3): 199–222. https://doi.org/10.5534/wjmh.180032

Zitzmann M., Soave A., Bier S. Functional testosterone deficiency in aging men: clinical impact, diagnostic pathways, and treatment strategies. Maturitas. 2026; 207: 108870. https://doi.org/10.1016/j.maturitas.2026.108870

Zitzmann M., Rastrelli G., Murray R.D. et al. Cardiovascular safety of testosterone therapy – insights from the TRAVERSE trial and beyond: a position statement of the European Expert Panel for Testosterone Research. Andrology. 2026; 14(1): 294–302. https://doi.org/10.1111/andr.70062

Theodorakis N., Kreouzi M., Hitas C. et al. Testosterone replacement therapy in heart failure: a systematic review of randomized controlled trials. Hormones (Athens). 2025; 24(3): 679–693. https://doi.org/10.1007/s42000-025-00658-y

Traish A.M. Major cardiovascular disease risk in men with testosterone deficiency (hypogonadism): appraisal of short, medium and long-term testosterone therapy – a narrative review. Sex Med Rev. 2023; 1(4): 384–394. https://doi.org/10.1093/sxmrev/qead031

Baas W., Köhler T.S. Testosterone replacement therapy and BPH/LUTS. What is the evidence? Curr Urol Rep. 2016; 17(6): 46. https://doi.org/10.1007/s11934-016-0600-8

Miranda E.P., Torres L.O. Late-onset hypogonadism: prostate safety. Andrology. 2020; 8(6): 1606–1613. https://doi.org/10.1111/andr.12772

Calogero A.E., Burgio G., Condorelli R.A. et al. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male. 2019; 22(1): 12–19. https://doi.org/10.1080/13685538.2018.1434772

Kohn T.P., Mata D.A., Ramasamy R., Lipshultz L.I. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur Urol. 2016; 69(6): 1083–1090. https://doi.org/10.1016/j.eururo.2016.01.043

Baas W., Köhler T.S. Testosterone replacement therapy and voiding dysfunction. Transl Androl Urol. 2016; 5(6): 890–897. https://doi.org/10.21037/tau.2016.08.11

Камалов А., Чалый М., Охоботов Д., Василевский Р. Андрогенный скрининг у мужчин с заболеваниями предстательной железы. Врач. 2013; 1: 70–72. – EDN PYRDUF.

Ficarra V., Rossanese M., Zazzara M. et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep. 2014; 15(12): 463. https://doi.org/10.1007/s11934-014-0463-9

Sterne J.A.C., Savović J., Page M.J. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366: l4898. https://doi.org/10.1136/bmj.l4898

Wells G.A., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Electronic resource]. URL: . http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed: 17.04.2024).

Schubert M., Jockenhövel F. Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects. Journal of Endocrinological Investigation. 2005; 28(3 Suppl): 23–27.

Welén K., Damber J.E. Androgens, aging, and prostate health. Rev Endocr Metab Disord. 2022 Dec; 23(6): 1221–1231. https://doi.org/10.1007/s11154-022-09730-z

Keast J.R. Plasticity of pelvic autonomic ganglia and urogenital innervation. International Review of Cytology. 2006; 248: 141–208. https://doi.org/10.1016/S0074-7696(06)48003-7

Salmi S., Santti R., Gustafsson J.A., Mäkelä S. Co-localization of androgen receptor with estrogen receptor beta in the lower urinary tract of the male rat. Journal of Urology. 2001; 166(2): 674–677. https://doi.org/10.1016/S0022-5347(05)66041-7

Zong T., Huang X., Zhou W. et al. Advances in the development of phosphodiesterase 5 inhibitors. European Journal of Medicinal Chemistry. 2025; 287: 117365. https://doi.org/10.1016/j.ejmech.2025.117365

Stamatiou K., Perletti G., Magri V., Trinchieri A. The Role of 5-Phosphodiesterase Inhibitors (PDE-5I) in Current Benign Prostatic Hyperplasia Treatment: A Narrative Review. Medicina (Kaunas). 2024; 60(11): 1736. https://doi.org/10.3390/medicina60111736

van der Sluis T.M., Vis A.N., van Moorselaar R.J. et al. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer. BJU International. 2012; 109(2): 176–182. https://doi.org/10.1111/j.1464-410X.2011.10651.x

van der Sluis T.M., Meuleman E.J., van Moorselaar R.J. et al. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer. BJU International. 2012; 109(2): 183–188. https://doi.org/10.1111/j.1464-410X.2011.10652.x

Marks L.S., Mazer N.A., Mostaghel E., Hess D.L., Dorey F.J., Epstein J.I. et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006 Nov 15; 296(19): 2351–61. https://doi.org/10.1001/jama.296.19.2351

Page S.T., Lin D.W., Mostaghel E.A. et al. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial. Journal of Clinical Endocrinology and Metabolism. 2011; 96: 430–437. https://doi.org/10.1210/jc.2010-1865

Morgentaler A., Traish A.M. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. European Urology. 2009; 55: 310–320. https://doi.org/10.1016/j.eururo.2008.09.024

Xiang J., Zheng Y., Chen D. et al. The pathogenesis of benign prostatic hyperplasia and the roles of Prdx3, oxidative stress, pyroptosis and autophagy: a review. Frontiers in Oncology. 2025; 15: 1579539. https://doi.org/10.3389/fonc.2025.1579539

Inamura S., Terada N. Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options. International Journal of Urology. 2024; 31(9): 968–974. https://doi.org/10.1111/iju.15518

Fibbi B., Penna G., Morelli A. et al. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. International Journal of Andrology. 2010; 33: 475–488. https://doi.org/10.1111/j.1365-2605.2009.00972.x

Nickel J.C., Roehrborn C.G., O'Leary M.P. et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. European Urology. 2008; 54: 1379–1384. https://doi.org/10.1016/j.eururo.2007.11.026

Vlachopoulos C., Jackson G., Stefanadis C. et al. Erectile dysfunction in the cardiovascular patient. European Heart Journal. 2013; 34: 2034–2046. https://doi.org/10.1093/eurheartj/eht112

Kaplan S.A., Roehrborn C.G., McConnell J.D. et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. Journal of Urology. 2008; 180: 1030–1032; discussion 1032–1033. https://doi.org/10.1016/j.juro.2008.05.004

McConnell J.D., Roehrborn C.G., Bautista O.M. et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine. 2003; 349(25): 2387–2398. https://doi.org/10.1056/NEJMoa030656

Fan Y., Hu S., Liu J. et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators of Inflammation. 2014; 2014: 397815. https://doi.org/10.1155/2014/397815

Wu Z.L., Yuan Y., Geng H., et al. Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue. Asian Journal of Andrology. 2012; 14: 316–319. https://doi.org/10.1038/aja.2011.154

Trifiro M.D., Parsons J.K., Palazzi-Churas K., et al. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU International. 2010; 105: 1554–1559. https://doi.org/10.1111/j.1464-410X.2009.09090.x

Kobelt G., Borgström F., Mattiasson A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU International. 2003; 91: 190–195. https://doi.org/10.1046/j.1464-410x.2003.04062.x

Asplund R., Marnetoft S.U., Selander J., Akerström B. Nocturia in relation to somatic health, mental health and pain in adult men and women. BJU International. 2005; 95: 816–819. https://doi.org/10.1111/j.1464-410X.2005.05407.x

van Kerrebroeck P., Abrams P., Chaikin D., et al. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourology and Urodynamics. 2002; 21: 179–183. https://doi.org/10.1002/nau.10053

Nakagawa H., Niu K., Hozawa A., et al. Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. Journal of Urology. 2010; 184: 1413–1418. https://doi.org/10.1016/j.juro.2010.05.093

Kim S.O., Choi H.S., Kim Y.J., et al. Impact of nocturia on health-related quality of life and medical outcomes study sleep score in men. International Neurourology Journal. 2011; 15: 82–86. https://doi.org/10.5213/inj.2011.15.2.82

Homma Y., Yamaguchi O., Hayashi K.; Neurogenic Bladder Society Committee. Epidemiologic survey of lower urinary tract symptoms in Japan. Urology. 2006; 68: 560–564. https://doi.org/10.1016/j.urology.2006.03.035

Tikkinen K.A., Tammela T.L., Huhtala H., Auvinen A. Is nocturia equally common among men and women? A population based study in Finland. Journal of Urology. 2006; 175: 596–600. https://doi.org/10.1016/S0022-5347(05)00245-4

Asplund R. Nocturia in relation to sleep, somatic diseases and medical treatment in the elderly. BJU International. 2002; 90: 533–536. https://doi.org/10.1046/j.1464-410x.2002.02975.x

Fitzgerald M.P., Litman H.J., Link C.L., McKinlay J.B.; BACH Survey Investigators. The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey. Journal of Urology. 2007; 177: 1385–1389. https://doi.org/10.1016/j.juro.2006.11.057

Yoshimura K., Terada N., Matsui Y., Terai A., Kinukawa N., Arai Y. Prevalence of and risk factors for nocturia: analysis of a health screening program. International Journal of Urology. 2004; 11: 282–287. https://doi.org/10.1111/j.1442-2042.2004.00791.x

Harman S.M., Metter E.J., Tobin J.D., Pearson J., Blackman M.R.; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Journal of Clinical Endocrinology and Metabolism. 2001; 86: 724–731. https://doi.org/10.1210/jcem.86.2.7219

Lunenfeld B., Mskhalaya G., Zitzmann M., et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015; 18: 5–15. https://doi.org/10.3109/13685538.2015.1004049

Bassil N., Alkaade S., Morley J.E. The benefits and risks of testosterone replacement therapy: a review. Therapeutics and Clinical Risk Management. 2009; 5: 427–448. https://doi.org/10.2147/tcrm.s3025

Huhtaniemi I. Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment. Asian Journal of Andrology. 2014; 16: 192–202. https://doi.org/10.4103/1008-682X.122336

Shigehara K., Namiki M. Late-onset hypogonadism syndrome and lower urinary tract symptoms. Korean Journal of Urology. 2011; 52: 657–663. https://doi.org/10.4111/kju.2011.52.10.657

Karazindiyanoğlu S., Cayan S. Shigehara therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male. 2008; 11: 146–149. https://doi.org/10.1080/13685530802290438

Al-Zoubi R.M., Alwani M., Aboumarzouk O.M., et al. Updates on androgen replacement therapy and lower urinary tract symptoms: a narrative review. Aging Male. 2022; 25(1): 234–241. https://doi.org/10.1080/13685538.2022.2118253

Wittert G. The relationship between sleep disorders and testosterone in men. Asian Journal of Andrology. 2014; 16: 262–265. https://doi.org/10.4103/1008-682X.122586

Schmid S.M., Hallschmid M., Jauch-Chara K., Lehnert H., Schultes B. Sleep timing may modulate the effect of sleep loss on testosterone. Clinical Endocrinology (Oxford). 2012; 77: 749–754. https://doi.org/10.1111/j.1365-2265.2012.04419.x

Oh M.M., Kim J.W., Jin M.H., Kim J.J., Moon du G. Influence of paradoxical sleep deprivation and sleep recovery on testosterone level in rats of different ages. Asian Journal of Andrology. 2012; 14: 330–334. https://doi.org/10.1038/aja.2011.153

Liao C.H., Chiang H.S., Yu H.J. Serum testosterone levels significantly correlate with nocturia in men aged 40-79 years. Urology. 2011; 78: 631–635. https://doi.org/10.1016/j.urology.2011.05.033

Kim J.W., Oh M.M., Yoon C.Y., Bae J.H., Kim J.J., Moon du G. Nocturnal polyuria and decreased serum testosterone: is there an association in men with lower urinary tract symptoms? International Journal of Urology. 2014; 21: 518–523. https://doi.org/10.1111/iju.12345

Kim M.K., Zhao C., Kim S.D., Kim D.G., Park J.K. Relationship of sex hormones and nocturia in lower urinary tract symptoms induced by benign prostatic hyperplasia. Aging Male. 2012; 15: 90–95. https://doi.org/10.3109/13685538.2012.659715

Liu H.Y., Chung M.S., Wang H.J., Liu R.T., Chuang Y.C. Nocturia indicates a poor health status and increases mortality in male patients with type 2 diabetes mellitus. International Urology and Nephrology. 2016; 48: 1209–1214. https://doi.org/10.1007/s11255-016-1310-3

Wu Y., Pan H., Wang W.M., Xu D., Zhang L., Gu Z.Q. et al. A possible relationship between serum sex hormones and benign prostatic hyperplasia/lower urinary tract symptoms in men who underwent transurethral prostate resection. Asian Journal of Andrology. 2017; 19: 230–233. https://doi.org/10.4103/1008-682X.171575

Kim J.W., Chae J.Y., Kim J.W., Yoon C.Y., Oh M.M., Park H.S. et al. Can treatment of nocturia increase testosterone level in men with late onset hypogonadism? Urology. 2014; 83: 837–842. https://doi.org/10.1016/j.urology.2013.12.060

Jeh S.U., Yoon S., Seo D.H., Lee S.W., Lee C., Choi S.M. et al. Relationship between serum testosterone and nocturia in men without benign prostate enlargement. Andrology. 2017; 5: 58–62. https://doi.org/10.1111/andr.12270

Yoo S.S., Shim B.S., Lee D.H., Lee H.W., Yoon H. Correlation between nocturia and sleep: a questionnaire based analysis. Korean Journal of Urology. 2010; 51: 757–762. https://doi.org/10.4111/kju.2010.51.11.757

Luboshitzky R., Zabari Z., Shen-Orr Z., Herer P., Lavie P. Disruption of the nocturnal testosterone rhythm by sleep fragmentation in normal men. Journal of Clinical Endocrinology and Metabolism. 2001; 86: 1134–1139. https://doi.org/10.1210/jcem.86.3.7296

Barrett-Connor E., Dam T.T., Stone K., Harrison S.L., Redline S., Orwoll E. Osteoporotic Fractures in Men Study Group. The association of testosterone levels with overall sleep quality, sleep architecture, and sleep-disordered breathing. Journal of Clinical Endocrinology and Metabolism. 2008; 93: 2602–2609. https://doi.org/10.1210/jc.2007-2622

Paul K.N., Laposky A.D., Turek F.W. Reproductive hormone replacement alters sleep in mice. Neuroscience Letters. 2009; 463: 239–243. https://doi.org/10.1016/j.neulet.2009.07.081

Shigehara K., Konaka H., Koh E., Izumi K., Kitagawa Y., Mizokami A., et al. Effects of testosterone replacement therapy on nocturia and quality of life in men with hypogonadism: a subanalysis of a previous prospective randomized controlled study in Japan. Aging Male. 2015; 18: 169–174. https://doi.org/10.3109/13685538.2015.1038990

Liu P.Y., Yee B., Wishart S.M., Jimenez M., Jung D.G., Grunstein R.R. et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. Journal of Clinical Endocrinology and Metabolism. 2003; 88: 3605–3613. https://doi.org/10.1210/jc.2003-030236

Hanafy H.M. Testosterone therapy and obstructive sleep apnea: is there a real connection? Journal of Sexual Medicine. 2007; 4: 1241–1246. https://doi.org/10.1111/j.1743-6109.2007.00553.x

Pávó I., Varga C., Szücs M., László F., Szécsi M., Gardi J., et al. Effects of testosterone on the rat renal medullary vasopressin receptor concentration and the antidiuretic response. Life Sciences. 1995; 56: 1215–1222. https://doi.org/10.1016/0024-3205(95)00061-a

Herzberg N.H., Goudsmit E., Kruisbrink J., Boer G.J. Testosterone treatment restores reduced vasopressin-binding sites in the kidney of the ageing rat. Journal of Endocrinology. 1989; 123: 59–63. https://doi.org/10.1677/joe.0.1230059

Pak T.R., Chung W.C., Hinds L.R., Handa R.J. Estrogen receptor-beta mediates dihydrotestosterone-induced stimulation of the arginine vasopressin promoter in neuronal cells. Endocrinology. 2007; 148: 3371–3382. https://doi.org/10.1210/en.2007-0086

Ikeda Y., Tanaka I., Oki Y., Gemmma R., Morita H., Komatsu K., et al. Testosterone normalizes plasma vasopressin response to osmotic stimuli in men with hypogonadism. Endocrine Journal. 1993; 40: 387–392. https://doi.org/10.1507/endocrj.40.387

Mitterberger M., Pallwein L., Gradl J., Frauscher F., Neuwirt H., Leunhartsberger N., et al. Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. BJU International. 2007; 99: 831–835. https://doi.org/10.1111/j.1464-410X.2006.06735.x

McVary K.T. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. European Urology. 2005; 47: 838–845. . https://doi.org/10.1016/j.eururo.2005.02.001

Azadzoi K.M., Tarcan T., Kozlowski R., Krane R.J., Siroky M.B. Overactivity and structural changes in the chronically ischemic bladder. Journal of Urology. 1999; 162: 1768–1778. https://doi.org/10.1016/S0022-5347(05)68236-5

Saad F., Gooren L.J., Haider A., Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. Journal of Andrology. 2008; 29: 102–105. https://doi.org/10.2164/jandrol.107.002774

Kalinchenko S., Vishnevskiy E.L., Koval A.N., Mskhalaya G.J., Saad F. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male. 2008; 11: 57–61. https://doi.org/10.1080/13685530801953994

Amano T., Imao T., Takemae K., Iwamoto T., Nakanome M. Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients. Aging Male. 2010; 13: 242–246. https://doi.org/10.3109/13685538.2010.487552

Ko Y.H., Moon du G., Moon K.H. Testosterone replacement alone for testosterone deficiency syndrome improves moderate lower urinary tract symptoms: one year follow-up. World Journal of Men's Health. 2013; 31: 47–52. https://doi.org/10.5534/wjmh.2013.31.1.47

Yassin A., Nettleship J.E., Talib R.A., Almehmadi Y., Doros G. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016; 19: 64–69. https://doi.org/10.3109/13685538.2015.1126573

US Food and Drug Administration. Testosterone Replacement Therapy: Current Regulatory Landscape. Christine P. Nguyen, M.D., Deputy Director for Safety. Division of Bone, Reproductive, and Urologic Products Office of Drug Evaluation III. Office of New Drugs 2. Available from: . https://www.fda.gov/media/123591/download

Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. Journal of Urology. 2002; 167: 948–951. discussion 952. https://doi.org/10.1016/S0022-5347(02)80307-X

Moore A., Butcher M.J., Kohler T.S. Testosterone replacement therapy on the natural history of prostate disease. Current Urology Reports. 2015; 16: 51. https://doi.org/10.1007/s11934-015-0526-6

St Sauver J.L., Jacobson D.J., McGree M.E. et al. Associations between longitudinal changes in serum estrogen, testosterone, and bioavailable testosterone and changes in benign urologic outcomes. American Journal of Epidemiology. 2011; 173: 787–796. https://doi.org/10.1093/aje/kwq438

Bhasin S., Woodhouse L., Casaburi R. et al. Testosterone dose-response relationships in healthy young men. American Journal of Physiology. Endocrinology and Metabolism. 2001; 281: E1172–E1181. https://doi.org/10.1152/ajpendo.2001.281.6.E1172

Cooper C.S., Perry P.J., Sparks A.E. et al. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. Journal of Urology. 1998; 159: 441–443. https://doi.org/10.1016/S0022-5347(01)63944-2

Emmelot-Vonk M.H., Verhaar H.J., Nakhai Pour H.R. et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. Journal of the American Medical Association. 2008; 299: 39–52. https://doi.org/10.1001/jama.2007.51

Bhasin S., Woodhouse L., Casaburi R. et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. Journal of Clinical Endocrinology and Metabolism. 2005; 90: 678–688. https://doi.org/10.1210/jc.2004-1184

Nair K.S., Rizza R.A., O'Brien P. et al. DHEA in elderly women and DHEA or testosterone in elderly men. New England Journal of Medicine. 2006; 355: 1647–1659. https://doi.org/10.1056/NEJMoa054629

Cui Y., Zhang Y. The effect of androgen-replacement therapy on prostate growth: a systematic review and meta-analysis. European Urology. 2013; 64: 811–822. https://doi.org/10.1016/j.eururo.2013.03.042

Barry M.J., Cockett A.T., Holtgrewe H.L. et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. Journal of Urology. 1993; 150: 351–358. https://doi.org/10.1016/S0022-5347(17)35482-4

Araujo A.B., Dixon J.M., Suarez E.A., et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism. 2011; 96: 3007–3019. https://doi.org/10.1210/jc.2011-1137

Matsumoto A.M. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2002; 57: M76–M99. https://doi.org/10.1093/gerona/57.2.M76

Rao P.M., Kelly D.M., Jones T.H. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nature Reviews. Endocrinology. 2013; 9: 479–493. https://doi.org/10.1038/nrendo.2013.122

Shores M.M., Matsumoto A.M. Testosterone, aging and survival: biomarker or deficiency. Current Opinion in Endocrinology, Diabetes and Obesity. 2014; 21: 209–216. https://doi.org/10.1097/MED.0000000000000057

Castro J.E., Griffiths H.J., Shackman R. Significance of signs and symptoms in benign prostatic hypertrophy. British Medical Journal. 1969; 2: 598–601. https://doi.org/10.1136/bmj.2.5657.598

Crawford E.D., Wilson S.S., McConnell J.D. et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. Journal of Urology. 2006; 175: 1422–1426; discussion 1426–1427. https://doi.org/10.1016/S0022-5347(05)00708-1

Saad F., Gooren L., Haider A. et al. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Archives of Andrology. 2007; 53: 353–357. https://doi.org/10.1080/01485010701730880

Yassin D.J., Doros G., Hammerer P.G. et al. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. Journal of Sexual Medicine. 2014; 11: 1567–1576. https://doi.org/10.1111/jsm.12523